Surgicure Technologies

Executive Summary

Surgicure Technologies, an Austin-based medical device company, aims to transform airway management with its patented HORSESHOE™ endotracheal tube securement device. The device addresses critical issues in intensive care: unplanned extubations (UEX), which occur in 10-15% of intubated patients, and facial pressure injuries from traditional tape-based securement. The HORSESHOE™ provides a secure, comfortable, and repositionable solution that also facilitates oral care, reducing complications and improving patient outcomes. The company targets a large market of critically ill patients across hospitals, emergency departments, and long-term acute care facilities, where airway management is a routine yet high-risk procedure. Surgicure is at an early stage, having developed its product concept and likely pursuing regulatory clearance. While specific financial details are undisclosed, the company's focus on a well-documented clinical need positions it well for adoption. The HORSESHOE™ offers potential cost savings by reducing UEX-related extended stays and injuries. Success hinges on proving efficacy through clinical studies, securing regulatory approvals, and building commercial traction. With a strong patent position and a growing emphasis on patient safety, Surgicure has a promising trajectory. The next 12-18 months will be critical as it advances toward market entry.

Upcoming Catalysts (preview)

• Q4 2026FDA 510(k) Clearance for HORSESHOE Device70% success
• Q2 2027First Hospital Partnership or Pilot Program60% success
• Q1 2027Publication of Clinical Outcomes Data55% success